Stock Track | Hims & Hers Soars 5.18% in Pre-Market on Potential for Alternative Weight Loss Drug Sales

Stock Track

Feb 28, 2025

Hims & Hers Health Inc. (HIMS) stock surged 5.18% in pre-market trading on Friday, following news that the company plans to explore alternative weight loss drug options after being forced to halt sales of its off-brand version of Ozempic.

The millennial-focused telehealth company had profited heavily in 2024 from selling a compounded version of semaglutide, the active ingredient in Novo Nordisk's popular Ozempic and Wegovy weight loss treatments. However, with the FDA removing semaglutide from its drug shortage list, Hims & Hers will soon be required to stop selling its cheaper alternative.

Despite this setback, Hims & Hers still has plans to offer other generic weight loss drugs, including liraglutide. According to reports, the company intends to start selling a generic version of liraglutide later this year, providing an alternative option for customers seeking affordable weight management solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170595716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170595716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170595716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170595716","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Soars 5.18% in Pre-Market on Potential for Alternative Weight Loss Drug Sales","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock surged 5.18% in pre-market trading on Friday, following news that the company plans to explore alternative weight loss drug options after being forced to halt sales of its off-brand version of Ozempic.</p>\n\n<p>The millennial-focused telehealth company had profited heavily in 2024 from selling a compounded version of semaglutide, the active ingredient in Novo Nordisk's popular Ozempic and Wegovy weight loss treatments. However, with the FDA removing semaglutide from its drug shortage list, Hims & Hers will soon be required to stop selling its cheaper alternative.</p>\n\n<p>Despite this setback, Hims & Hers still has plans to offer other generic weight loss drugs, including liraglutide. According to reports, the company intends to start selling a generic version of liraglutide later this year, providing an alternative option for customers seeking affordable weight management solutions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Soars 5.18% in Pre-Market on Potential for Alternative Weight Loss Drug Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Soars 5.18% in Pre-Market on Potential for Alternative Weight Loss Drug Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock surged 5.18% in pre-market trading on Friday, following news that the company plans to explore alternative weight loss drug options after being forced to halt sales of its off-brand version of Ozempic.</p>\n\n<p>The millennial-focused telehealth company had profited heavily in 2024 from selling a compounded version of semaglutide, the active ingredient in Novo Nordisk's popular Ozempic and Wegovy weight loss treatments. However, with the FDA removing semaglutide from its drug shortage list, Hims & Hers will soon be required to stop selling its cheaper alternative.</p>\n\n<p>Despite this setback, Hims & Hers still has plans to offer other generic weight loss drugs, including liraglutide. According to reports, the company intends to start selling a generic version of liraglutide later this year, providing an alternative option for customers seeking affordable weight management solutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1170595716","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170595716","pubTimestamp":1740754835,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  stock surged 5.18% in pre-market trading on Friday, following news that the company plans to explore alternative weight loss drug options after being forced to halt sales of its off-brand version of Ozempic.The millennial-focused telehealth company had profited heavily in 2024 from selling a compounded version of semaglutide, the active ingredient in Novo Nordisk's popular Ozempic and Wegovy weight loss treatments. However, with the FDA removing semaglutide from its drug","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票跟踪Hims&Hers盘前飙升5.18%，因替代减肥药销售潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock surged 5.18% in pre-market trading on Friday, following news that the company plans to explore alternative weight loss drug options after being forced to halt sales of its off-brand version of Ozempic.\nThe millennial-focused telehealth company had profited heavily in 2024 from selling a compounded version of semaglutide, the active ingredient in Novo Nordisk's popular Ozempic and Wegovy weight loss treatments. However, with the FDA removing semaglutide from its drug shortage list, Hims & Hers will soon be required to stop selling its cheaper alternative.\nDespite this setback, Hims & Hers still has plans to offer other generic weight loss drugs, including liraglutide. According to reports, the company intends to start selling a generic version of liraglutide later this year, providing an alternative option for customers seeking affordable weight management solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}